Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.